JP2021527039A5 - - Google Patents

Info

Publication number
JP2021527039A5
JP2021527039A5 JP2020567578A JP2020567578A JP2021527039A5 JP 2021527039 A5 JP2021527039 A5 JP 2021527039A5 JP 2020567578 A JP2020567578 A JP 2020567578A JP 2020567578 A JP2020567578 A JP 2020567578A JP 2021527039 A5 JP2021527039 A5 JP 2021527039A5
Authority
JP
Japan
Prior art keywords
patent document
document
application publication
prior
patent application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021527039A (ja
JP7794564B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035576 external-priority patent/WO2019236703A1/en
Publication of JP2021527039A publication Critical patent/JP2021527039A/ja
Publication of JP2021527039A5 publication Critical patent/JP2021527039A5/ja
Priority to JP2024056596A priority Critical patent/JP2024096738A/ja
Application granted granted Critical
Publication of JP7794564B2 publication Critical patent/JP7794564B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567578A 2018-06-05 2019-06-05 悪性リンパ腫性障害の治療法 Active JP7794564B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024056596A JP2024096738A (ja) 2018-06-05 2024-03-29 悪性リンパ腫性障害の治療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862680739P 2018-06-05 2018-06-05
US62/680,739 2018-06-05
PCT/US2019/035576 WO2019236703A1 (en) 2018-06-05 2019-06-05 Methods of treating malignant lymphoproliferative disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024056596A Division JP2024096738A (ja) 2018-06-05 2024-03-29 悪性リンパ腫性障害の治療法

Publications (3)

Publication Number Publication Date
JP2021527039A JP2021527039A (ja) 2021-10-11
JP2021527039A5 true JP2021527039A5 (cg-RX-API-DMAC7.html) 2022-06-13
JP7794564B2 JP7794564B2 (ja) 2026-01-06

Family

ID=68769443

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020567578A Active JP7794564B2 (ja) 2018-06-05 2019-06-05 悪性リンパ腫性障害の治療法
JP2024056596A Pending JP2024096738A (ja) 2018-06-05 2024-03-29 悪性リンパ腫性障害の治療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024056596A Pending JP2024096738A (ja) 2018-06-05 2024-03-29 悪性リンパ腫性障害の治療法

Country Status (11)

Country Link
US (3) US11510904B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801768A4 (cg-RX-API-DMAC7.html)
JP (2) JP7794564B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210045364A (cg-RX-API-DMAC7.html)
CN (2) CN112351819B (cg-RX-API-DMAC7.html)
AU (1) AU2019280693B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020024931A2 (cg-RX-API-DMAC7.html)
CA (1) CA3102555A1 (cg-RX-API-DMAC7.html)
IL (2) IL279155B2 (cg-RX-API-DMAC7.html)
MX (2) MX2020013163A (cg-RX-API-DMAC7.html)
WO (1) WO2019236703A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801768A4 (en) * 2018-06-05 2022-04-20 Actuate Therapeutics Inc. METHODS OF TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANT DISEASES
IL294369A (en) * 2019-12-26 2022-08-01 Actuate Therapeutics Inc Compounds for the treatment of myelofibrosis
US20240009170A1 (en) * 2020-11-17 2024-01-11 Brown University Inhibition of glycogen synthase kinase-3 (gsk-3)
JP2022157223A (ja) * 2021-03-31 2022-10-14 国立大学法人神戸大学 抗ガン剤効果増強剤
CN113684180B (zh) * 2021-08-31 2023-05-26 山东大学第二医院 一种提高骨髓瘤杀伤活性的nk细胞制备方法
WO2023172629A2 (en) * 2022-03-08 2023-09-14 Brown University Anticancer maleimide derivatives for use with immune checkpoint blockade
CA3251821A1 (en) * 2022-06-27 2024-01-04 Actuate Therapeutics, Inc. ORAL DOSAGE FORMS OF ELRAGLUSIB
US20260060969A1 (en) * 2022-08-04 2026-03-05 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
WO2025245059A1 (en) * 2024-05-23 2025-11-27 Yale University Compositions comprising gsk-3 and/or beta-catenin inhibitors and/or degraders and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
EA024939B1 (ru) 2012-02-21 2016-11-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов гликогенсинтазы киназы 3-бета
DK2909204T3 (en) 2012-10-12 2019-04-01 Broad Inst Inc GSK3 INHIBITORS AND METHODS FOR USE THEREOF
US20160375006A1 (en) * 2012-10-12 2016-12-29 The Broad Institute, Inc. Uses of paralog-selective inhibitors of gsk3 kinases
WO2014165851A1 (en) * 2013-04-05 2014-10-09 The Children's Hospital Of Philadelphia Transient up-regulation of myc in b-cell lymphomas
WO2015155738A2 (en) * 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
JP6534098B2 (ja) * 2014-09-12 2019-06-26 国立大学法人 鹿児島大学 成人t細胞白血病治療薬
EP3801768A4 (en) * 2018-06-05 2022-04-20 Actuate Therapeutics Inc. METHODS OF TREATMENT OF LYMPHOPROLIFERATIVE MALIGNANT DISEASES
US20210299233A1 (en) * 2018-07-12 2021-09-30 The Children's Medical Center Corporation Method for treating cancer

Similar Documents

Publication Publication Date Title
NO20080362L (no) CD19-antistoffer og deres anvendelser
MX374906B (es) Nuevos inmunoconjugados
MX2024002353A (es) Celulas asesinas naturales modificadas geneticamente.
JP2014087372A5 (cg-RX-API-DMAC7.html)
JP2019502892A5 (cg-RX-API-DMAC7.html)
SA520411173B1 (ar) Pd-l1 عوامل ربط ترتبط بـ واستخدامها cd137
EA201170492A1 (ru) Векторы для генной терапии и цитозиндезаминазы
JP2013517798A5 (cg-RX-API-DMAC7.html)
PH12022553257A1 (en) Antibodies to tigit
FI2884999T4 (fi) Menetelmä ja koostumuksia soluimmunoterapiaa varten
NO20073797L (no) Humane monoklonale antistoffer mot prostata spesifikt membran antigen (PSMA)
Salnikov et al. The viral etiology of EBV-associated gastric cancers contributes to their unique pathology, clinical outcomes, treatment responses and immune landscape
CY1118442T1 (el) Μεθοδοι αγωγης δια της χρησεως εκλεκτικων αναστολεων bcl-2
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
JP2014519854A5 (cg-RX-API-DMAC7.html)
MX2018007249A (es) Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este.
Pei et al. Current progress in EBV-associated B-cell lymphomas
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
EA200602241A1 (ru) Замещённые индазолы, композиции, содержащие указанные индазолы, способ их получения и применение
EA200800229A1 (ru) Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1)
TN2011000283A1 (en) Human cgrp receptor binding proteins
UA108442C2 (ru) Индазолы
MY195289A (en) Anti IL-36R Antibodies
JP2018525453A5 (cg-RX-API-DMAC7.html)
JP2015525207A5 (cg-RX-API-DMAC7.html)